Nuvectis Pharma, Inc.
NVCT
$0.05
Change (1 day)
$12.10
Year High
$4.61
Year Low
Categories
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Earnings for Nuvectis Pharma, Inc. (NVCT)
Earnings in 2023 (TTM): $-22,260,000
According to Nuvectis Pharma, Inc.'s latest financial reports the company's current earnings (TTM) are $-22,260,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Nuvectis Pharma, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-22,260,000 | $-22,260,000 |
| 2022 | $-19,085,000 | $-18,787,000 |
| 2021 | $-12,890,000 | $-12,886,000 |
| 2020 | $-10,000 | $-10,000 |